Abstract
Diabetes is one of the most common human diseases. In various countries of the world, the number of patients with diabetes is 4-7 % of the total population. The incidence of diabetes increases with age and reaches 10-15% after the age of 65. The prevalence of diabetes in the world has a significant tendency to increase. A comparison of the prevalence of diabetes shows that in developed countries, a significant increase in diabetes is predicted for 2030 in people over 65; at the same time, developing countries are characterized by an increase in the number of diabetes patients aged 45-64. Today, there are 371 million people with diabetes in the world, and by 2025, 552 million people with diabetes are expected. Epidemiological studies of diabetes in Ukraine indicate a constant increase in the number of patients. This clinical guideline (CG) is a version of the clinical guideline of the American Diabetes Association (ADA) Releases Standards of Medical Care in Diabetes, 2021, USA, adapted for the health care system of Ukraine, which was chosen by the working group as an example of the best practice of providing medical care assistance to patients with diabetes and is based on evidence-based medicine data regarding the effectiveness and safety of medical interventions, pharmacotherapy and organisational principles of its provision. The clinical guideline was selected on the basis of objective evaluation criteria using an international tool — the AGREE II Guideline Expertise and Evaluation Questionnaire. The proposed CG should not be regarded as a standard of medical treatment. Compliance with the provisions of the CG is not a guarantee of successful treatment in each specific case, it cannot be considered as a guide that includes all necessary treatment methods or, on the contrary, excludes others. The final decision regarding the choice of a specific clinical procedure or treatment plan should be made by the doctor, taking into account the clinical condition of the patient and the possibilities for carrying out diagnostic and treatment measures in a medical institution. CG “Diabetes” aims to provide assistance to the doctor and patient in making a rational decision in various clinical situations, is informational support for improving the quality of clinical practice based on evidence of the effectiveness of the use of certain medical technologies, drugs and organisational resources of medical care.
Key words: diabetes, American Diabetes Association, Standards of Medical Care in Diabetes, Ukraine, medical care
References:
1. Clement S, Braithwaite SS, Magee MF, et al.; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553–591 [published corrections appear in Diabetes Care 2004;27:856 and Diabetes Care 2004;27:1255]
2. Moghissi ES, Korytkowski MT, DiNardo M, et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119–1131
3. Bogun M, Inzucchi SE. Inpatient management of diabetes and hyperglycemia. Clin Ther 2013; 35:724–733
4. Moghissi E, Inzucchi S. The evolution of glycemic control in the hospital setting. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 1–10
5. Umpierrez G, Korytkowski M. Diabetic emergencies – ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 2016;12:222–232
6. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care 2015;38: e202–e203
7. Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care 2014;37:2934– 2939
8. Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and impact of unknown diabetes in the ICU. Crit Care Med 2015; 43:e541–e550
9. Rhee MK, Safo SE, Jackson SL, et al. Inpatient glucose values: determining the nondiabetic range and use in identifying patients at high risk for diabetes. Am J Med 2018;131:443.e11– 443.e24
10. Garg R, Schuman B, Bader A, et al. Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery. Ann Surg 2018;267:858–862
11. van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan G-O, Dunson DB. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care 2018;41:782–788
12. Setji T, Hopkins TJ, Jimenez M, et al. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost. Diabetes Spectr 2017;30:217–223
13. Okabayashi T, Shima Y, Sumiyoshi T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care 2014;37:1516–1524
14. Institute of Medicine. Preventing Medication Errors. Aspden P, Wolcott J, Bootman JL, Cronenwett LR, Eds. Washington, DC, National Academies Press, 2007
15. Gillaizeau F, Chan E, Trinquart L, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2013;11:CD002894
16. Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness of a computerized insulin order template in general medical inpatients with type 2 diabetes: a cluster randomized trial. Diabetes Care 2010;33:2181–2183
17. Schnipper JL, Liang CL, Ndumele CD, Pendergrass ML. Effects of a computerized order set on the inpatient management of hyperglycemia: a cluster-randomized controlled trial. Endocr Pract 2010;16:209–218
18. Wang YJ, Seggelke S, Hawkins RM, et al. Impact of glucose management team on outcomes of hospitalization in patients with type 2 diabetes admitted to the medical service. Endocr Pract 2016;22:1401–1405
19. Draznin B, Gilden J, Golden SH, et al.; PRIDE investigators. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care 2013;36:1807–1814
20. Bansal V, Mottalib A, Pawar TK, et al. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. BMJ Open Diabetes Res Care 2018;6:e000460
21. Ostling S, Wyckoff J, Ciarkowski SL, et al. The relationship between diabetes mellitus and 30-day readmission rates. Clin Diabetes Endocrinol 2017;3:3
22. Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study. Ann Intern Med 2017;166:621–627
23. Arnold P, Scheurer D, Dake AW, et al. Hospital guidelines for diabetes management and the Joint Commission- American Diabetes Association inpatient diabetes certification. Am J Med Sci 2016;351:333–341
24. Society of Hospital Medicine. Glycemic control for hospitalists. Accessed 30 October 2020. Available from https://www.hospitalmedicine .org/clinical-topics/glycemic-control/
25. Umpierrez GE, Hellman R, Korytkowski MT, et al.; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:16– 38
26. Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017;40:1622–1630
27. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359–1367
28. Finfer S, Chittock DR, Su SY, et al.; NICESUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297
29. Kansagara D, Fu R, Freeman M, Wolf F, Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med 2011;154:268–282
30. Sathya B, Davis R, Taveira T, Whitlatch H, Wu WC. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2013;102:8–15
31. Umpierrez G, Cardona S, Pasquel F, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care 2015;38: 1665–1672
32. Duncan AE, Abd-Elsayed A, Maheshwari A, Xu M, Soltesz E, Koch CG. Role of intraoperative and postoperative blood glucose concentrations in predicting outcomes after cardiac surgery. Anesthesiology 2010;112:860–871
33. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract 2004;10(Suppl. 2):21–33
34. Wang CCL, Draznin B. Practical approach to management inpatient hyperglycemia in selected populations. Hosp Pract 2013;41: 45–53
35. Cobaugh DJ, Maynard G, Cooper L, et al. Enhancing insulin-use safety in hospitals: practical recommendations from an ASHP Foundation expert consensus panel. Am J Health Syst Pharm 2013;70:1404–1413
36. Rice MJ, Coursin DB. Glucose meters: here today, gone tomorrow? Crit Care Med 2016;44: e97–e100
37. Rice MJ, Smith JL, Coursin DB. Glucose measurement in the ICU: regulatory intersects reality. Crit Care Med 2017;45:741–743
38. Klonoff DC, Draznin B, Drincic A, et al. PRIDE statement on the need for a moratorium on the CMS plan to cite hospitals for performing pointof-care capillary blood glucose monitoring on critically ill patients. J Clin Endocrinol Metab 2015;100:3607–3612
39. DuBois JA, Slingerland RJ, Fokkert M, et al. Bedside glucose monitoringdis it safe? A new, regulatory-compliant risk assessment evaluation protocol in critically ill patient care settings. Crit Care Med 2017;45:567–574
40. Zhang R, Isakow W, Kollef MH, Scott MG. Performance of a modern glucose meter in ICU and general hospital inpatients: 3 years of realworld paired meter and central laboratory results. Crit Care Med 2017;45:1509–1514
41. Maynard G, Wesorick DH, O’Malley C, Inzucchi SE; Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med 2008; 3(Suppl.):29–41
42. Brown KE, Hertig JB. Determining current insulin pen use practices and errors in the inpatient setting. Jt Comm J Qual Patient Saf 2016; 42:568–AP7
43. Horne J, Bond R, Sarangarm P. Comparison of inpatient glycemic control with insulin vials versus insulin pens in general medicine patients. Hosp Pharm 2015;50:514–521
44. Veronesi G, Poerio CS, Braus A, et al. Determinants of nurse satisfaction using insulin pen devices with safety needles: an exploratory factor analysis. Clin Diabetes Endocrinol 2015; 1:15
45. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients. Accessed 30 October 2020. Available from https://www .fda.gov/Drugs/DrugSafety/ucm435271.htm
46. Bueno E, Benitez A, Rufinelli JV, et al. Basalbolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: a randomized controlled trial in Latin America. Endocr Pract 2015;21:807–813
47. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256–261
48. Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, et al. Sliding scale insulin for non-critically ill hospitalized adults with diabetes mellitus. Cochrane Database Syst Rev 2018;11:CD011296.pub2
49. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2016;51:417–428
50. Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38:2211–2216
51. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012;35:1970–1974
52. Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis. Curr Diab Rep 2018;18:75
53. Shomali ME, Herr DL, Hill PC, Pehlivanova M, Sharretts JM, Magee MF. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study. Diabetes Technol Ther 2011;13:121–126
54. Lien LF, Low Wang CC, Kreider KE, Baldwin D. Transitioning from intravenous to subcutaneous insilun. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 115–128
55. Tripathy PR, Lansang MC. U-500 regular insulin use in hospitalized patients. Endocr Pract 2015;21:54–58
56. Lansang MC, Umpierrez GE. Inpatient hyperglycemia management: a practical review for primary medical and surgical teams. Cleve Clin J Med 2016;83(Suppl. 1):S34–S43
57. Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care 2013;36:3430–3435
58. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital settingdis it time to revise the guidelines for the management of inpatient diabetes? Curr Diab Rep 2019;19:65
59. Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. J Diabetes Investig 2020;11:125–131
60. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care 2019;42:450– 456
61. Perez-Belmonte LM, Osuna-S ́ anchez J, ́ Millan-G ́ omez M, et al. Glycaemic ef ́ ficacy and safety of linagliptin for the management of noncardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. Ann Med 2019;51:252–261
62. Vellanki P, Rasouli N, Baldwin D, et al. Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicenter randomized clinical trial. Diabetes Obes Metab 2019;21:837–843
63. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Accessed 30 October 2020. Available from http://www .fda.gov/Drugs/DrugSafety/ucm486096.htm
64. Akirov A, Grossman A, Shochat T, Shimon I. Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related. J Clin EndocrinolMetab 2017;102:416–424
65. Amori RE, Pittas AG, Siegel RD, et al. Inpatient medical errors involving glucose-lowering medications and their impact on patients: review of 2,598 incidents from a voluntary electronic error-reporting database. Endocr Pract 2008;14:535–542
66. Alwan D, Chipps E, Yen P-Y, Dungan K. Evaluation of the timing and coordination of prandial insulin administration in the hospital. Diabetes Res Clin Pract 2017;131:18–32
67. Hung AM, Siew ED, Wilson OD, et al. Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury. Diabetes Care 2018;41:503–512
68. Maynard G, Kulasa K, Ramos P, et al. Impact of a hypoglycemia reduction bundle and a systems approach to inpatient glycemic management. Endocr Pract 2015;21:355–367
69. Milligan PE, Bocox MC, Pratt E, Hoehner CM, Krettek JE, Dunagan WC. Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system. Am J Health Syst Pharm 2015;72:1631–1641
70. Dagogo-Jack S. Hypoglycemia in type 1 diabetes mellitus: pathophysiology and prevention. Treat Endocrinol 2004;3:91–103
71. Rickels MR. Hypoglycemia-associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Ann N Y Acad Sci 2019;1454:68–79
72. Dendy JA, Chockalingam V, Tirumalasetty NN, et al. Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes. Endocr Pract 2014;20:1051–1056
73. Ulmer BJ, Kara A, Mariash CN. Temporal occurrences and recurrence patterns of hypoglycemia during hospitalization. Endocr Pract 2015;21:501–507
74. Shah BR, Walji S, Kiss A, James JE, Lowe JM. Derivation and validation of a risk-prediction tool for hypoglycemia in hospitalized adults with diabetes: the Hypoglycemia During Hospitalization (HyDHo) score. Can J Diabetes 2019;43: 278– 282.e1
75. Mathioudakis NN, Everett E, Routh S, et al. Development and validation of a prediction model for insulin-associated hypoglycemia in non-critically ill hospitalized adults. BMJ Open Diabetes Res Care 2018;6:e000499
76. Curll M, Dinardo M, Noschese M, Korytkowski MT. Menu selection, glycaemic control and satisfaction with standard and patientcontrolled consistent carbohydrate meal plans in hospitalised patients with diabetes. Qual Saf Health Care 2010;19:355–359
77. Korytkowski M, Draznin B, Drincic A. Food, fasting, insulin, and glycemic control in the hospital. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 70–83
78. Mabrey ME, Setji TL. Patient self-management of diabetes care in the inpatient setting: pro. J Diabetes Sci Technol 2015;9:1152–1154
79. Shah AD, Rushakoff RJ. Patient self-management of diabetes care in the inpatient setting: con. J Diabetes Sci Technol 2015;9: 1155–1157
80. Umpierrez GE, Klonoff DC. Diabetes technology update:use of insulin pumps and continuous glucosemonitoring in the hospital. Diabetes Care 2018;41:1579–1589
81. Houlden RL, Moore S. In-hospital management of adults using insulin pump therapy. Can J Diabetes 2014;38:126–133 82. Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care 2009;32:594–596
83. Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract 2011;26:714–717
84. Drincic AT, Knezevich JT, Akkireddy P. Nutrition and hyperglycemia management in the inpatient setting (meal on demand, parenteral, or enteral nutrition). Curr Diab Rep 2017;17:59–71
85. Low Wang CC, Hawkins RM, Gianchandani R, Dungan K. Glycemic control in the setting of parenteral or enteral nutrition via tube feeding. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 84–98
86. Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr Pract 2011;17:249–260
87. Roberts A, James J, Dhatariya K; Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 2018;35:1011– 1017
88. Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci 2013;345:274–277
89. Seggelke SA, Gibbs J, Draznin B. Pilot study of using NPH insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med 2011;6:175–176
90. Mathioudakis N, Dungan K, Baldwin D, Korytkpwski M, Reider J. Steroid-associated hyperglycemia. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 99–114
91. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basalbolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther 2014;16:874–879
92. SmileyDD,UmpierrezGE.Perioperativeglucose control in the diabetic or nondiabetic patient. South Med J 2006;99:580– 589; quiz 590–591
93. Buchleitner AM, Mart ́ınez-Alonso M, Hernandez M, Sol ́ a I, Mauricio D. Perioperative ` glycaemic control for diabetic patients undergoing surgery. Cochrane Database Syst Rev 2012; 9:CD007315
94. Gianchandani R, Dubois E, Alexanian S, Rushakoff R. Preoperative, intraoperative, and postoperative glucose management. In Managing Diabetes and Hyperglycemia in the Hospital Setting. Draznin B, Ed. Alexandria, VA, American Diabetes Association, 2016, pp. 129–144
95. Buchleitner AM, Mart ́ınez-Alonso M, Hernandez M, Sol ́ a I, Mauricio D. Perioperative ` glycaemic control for diabetic patients undergoing surgery. Cochrane Database Syst Rev 2012; 9:CD007315
96. Demma LJ, Carlson KT, Duggan EW, Morrow JG 3rd, Umpierrez G. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. J Clin Anesth 2017;36:184–188
97. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care 2013;36:2169–2174
98. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335–1343
99. Vellanki P, Umpierrez GE. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr Pract 2017;23:971–978
100. Harrison VS, Rustico S, Palladino AA, Ferrara C, Hawkes CP. Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen. Pediatr Diabetes 2017; 18:742– 748
101. Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 2012;97:3132–3137
102. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid- acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev 2016;1:CD011281
103. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008;93:1541– 1552
104. Shepperd S, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev 1996;1:CD000313
105. Agency for Healthcare Research and Quality. Readmissions and adverse events after discharge. Accessed 30 October 2020. Available from https://psnet.ahrq.gov/primers/ primer/11
106. Rubin DJ. Hospital readmission of patients with diabetes. Curr Diab Rep 2015;15:17
107. Gregory NS, Seley JJ, Dargar SK, Galla N, Gerber LM, Lee JI. Strategies to prevent readmission in high-risk patients with diabetes: the importance of an interdisciplinaryapproach. Curr Diab Rep 2018;18:54
108. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. Diabetes Care 2003;26:1421–1426
109. Maldonado MR, D’Amico S, Rodriguez L, Iyer D, Balasubramanyam A. Improved outcomes in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit. Endocr Pract 2003;9:26–32
110. Wu EQ, Zhou S, Yu A, et al. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract (1995) 2012;40:40–48
111. Hirschman KB, Bixby MB. Transitions in care from the hospital to home for patients with diabetes. Diabetes Spectr 2014;27:192– 195
112. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37: 2864–2883
113. Rubin DJ, Recco D, Turchin A, Zhao H, Golden SH. External validation of the Diabetes Early Re-admission Risk Indicator (DERRI). Endocr Pract 2018;24:527–541
Published:
2024-05-02
How to Cite:
Diabetes. Clinical guidelines (Final) The multidisciplinary team of authors
14. Management of diabetes in pregnancy: Standards of care for diabetes 2021
15. Diabetes care in the hospital: Standards of care for diabetes 2021
Diabetes Obesity Metabolic Syndrome, 13(2),, 8-34.